Paper
Assessment of Drug‐drug Interaction Potential of Enfuvirtide in Human Immunodeficiency Virus Type 1–infected Patients
Published Jun 1, 2004 · Xiaoping Zhang, J. Lalezari, A. Badley
Clinical Pharmacology & Therapeutics
Q1 SJR score
43
Citations
0
Influential Citations
Abstract
Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.
In Vitro StudyStudy Snapshot
Enfuvirtide does not significantly influence CYP enzyme activities in HIV-1-infected patients, suggesting its potential as a single drug for HIV-1 treatment.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.
Sign up to use Study Snapshot
Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.
Full text analysis coming soon...
References
Bioanalytical method development and validation for a large peptide HIV fusion inhibitor (Enfuvirtide, T-20) and its metabolite in human plasma using LC-MS/MS.
The developed method for measuring HIV fusion inhibitor T-20 and its metabolite M-20 in human plasma using LC-MS/MS provides pharmacokinetic profiles for clinical studies.
2005·55citations·D. Chang et al.·Journal of pharmaceutical and biomedical analysis
Journal of pharmaceutical and biomedical analysis
Lack of Enzyme‐Inducing Effect of Rifampicin on the Pharmacokinetics of Enfuvirtide
Rifampicin does not significantly influence the pharmacokinetics of enfuvirtide in HIV-1-infected patients, with no unexpected effects on short-term antiviral effect or safety.
2003·49citations·M. Boyd et al.·The Journal of Clinical Pharmacology
The Journal of Clinical Pharmacology
The karolinska cocktail for phenotyping of five human cytochrome P450 enzymes
The karolinska cocktail, consisting of caffeine, losartan, omeprazole, debrisoquin, and quinine, can be administered in low doses for phenotyping CYP enzymes, with a schedule designed to minimize sampling opportunities.
2003·158citations·M. Christensen et al.·Clinical Pharmacology & Therapeutics
Clinical Pharmacology & Therapeutics
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
Enfuvirtide added to an optimized antiretroviral regimen significantly improved antiretroviral and immunologic outcomes through 24 weeks in patients with multidrug-resistant HIV-1 infection.
2003·920citations·J. Lalezari et al.·The New England journal of medicine
The New England journal of medicine
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.
The optimal time to initiate antiretroviral therapy for adult HIV infection remains imprecise, but new drugs have broadened treatment options and improved treatment failure management.
2002·778citations·P. Yeni et al.·JAMA
JAMA
Citations
Drug-Drug Interaction Between Rifampicin and Albuvirtide: A Phase 1, Randomized, Open-Label Study.
Albuvirtide and rifampicin can be co-administered without requiring dose adjustments, as their pharmacokinetics change but do not significantly impact each other's effectiveness.
2025·0citations·Li Zhang et al.·Journal of clinical pharmacology
Journal of clinical pharmacology
Clinically Relevant Pharmacokinetic Herb-drug Interactions in Antiretroviral Therapy.
Clinically relevant herb-drug interactions exist, requiring caution when using antiretroviral drugs with St John's wort, black pepper, and grapefruit juice.
2015·28citations·P. Fasinu et al.·Current drug metabolism
Current drug metabolism
Drug-drug interactions: antiretroviral drugs and recreational drugs.
HIV patients treated with antiretroviral drugs may experience drug-drug interactions, especially with non-nucleoside reverse transcriptase inhibitors.
2015·12citations·O. Staltari et al.·Recent patents on CNS drug discovery
Recent patents on CNS drug discovery
Drug-drug interactions in ageing HIV-infected individuals
Ageing HIV-infected individuals face higher drug-drug interactions due to age-related changes in body physiology and polypharmacy, requiring careful management by healthcare professionals.
2012·1citation·P. Fasinu et al.·African Journal of Pharmacy and Pharmacology
African Journal of Pharmacy and Pharmacology
Expert opinion on pharmacotherapy of kidney disease in HIV-infected patients
Pharmacologic interventions for kidney disease in HIV-infected patients should be tailored to their unique needs, as many common medications can have adverse effects on kidneys.
2011·10citations·Zygimantas C. Alsauskas et al.·Expert Opinion on Pharmacotherapy
Expert Opinion on Pharmacotherapy